India, April 11 -- Swiss pharmaceutical titan Novartis has unveiled an ambitious plan to invest $23 billion over the next five years to bolster its U.S. manufacturing and research capacities.
The strategic initiative aims to ensure that all of its essential medications are produced on U.S. soil, underscoring the company's commitment to domestic production amid looming concerns over potential pharmaceutical tariffs.
The expansion will include the construction of seven new facilities, alongside significant upgrades to existing sites. A cornerstone of this initiative is a state-of-the-art $1.1 billion research and development hub to be built in San Diego, which will serve as the epicenter of Novartis' West Coast biomedical research efforts a...